Top

Published in:

Open Access 01-12-2008 | Hypothesis

Important genetic checkpoints for insulin resistance in salt-sensitive (S) Dahl rats

Author: Marlene F Shehata

Published in: Cardiovascular Diabetology | Issue 1/2008

Abstract

Despite the marked advances in research on insulin resistance (IR) in humans and animal models of insulin resistance, the mechanisms underlying high salt-induced insulin resistance remain unclear. Insulin resistance is a multifactorial disease with both genetic and environmental factors (such as high salt) involved in its pathogenesis. High salt triggers insulin resistance in genetically susceptible patients and animal models of insulin resistance. One of the mechanisms by which high salt might precipitate insulin resistance is through its ability to enhance an oxidative stress-induced inflammatory response that disrupts the insulin signaling pathway. The aim of this hypothesis is to discuss two complementary approaches to find out how high salt might interact with genetic defects along the insulin signaling and inflammatory pathways to predispose to insulin resistance in a genetically susceptible model of insulin resistance. The first approach will consist of examining variations in genes involved in the insulin signaling pathway in the Dahl S rat (an animal model of insulin resistance and salt-sensitivity) and the Dahl R rat (an animal model of insulin sensitivity and salt-resistance), and the putative cellular mechanisms responsible for the development of insulin resistance. The second approach will consist of studying the over-expressed genes along the inflammatory pathway whose respective activation might be predictive of high salt-induced insulin resistance in Dahl S rats.

Variations in genes encoding the insulin receptor substrates -1 and/or -2 (IRS-1, -2) and/or genes encoding the glucose transporter (GLUTs) proteins have been found in patients with insulin resistance. To better understand the combined contribution of excessive salt and genetic defects to the etiology of the disease, it is essential to investigate the following question:

Question 1: Do variations in genes encoding the IRS -1 and -2 and/or genes encoding the GLUTs proteins predict high salt-induced insulin resistance in Dahl S rats?

A significant amount of evidence suggested that salt-induced oxidative stress might predict an inflammatory response that upregulates mediators of inflammation such as the nuclear factor- kappa B (NF-kappa B), the tumor necrosis factor-alpha (TNF-α) and the c-Jun Terminal Kinase (JNK). These inflammatory mediators disrupt the insulin signaling pathway and predispose to insulin resistance. Therefore, the following question will be thoroughly investigated:

Question 2: Do variations in genes encoding the NF-kappa B, the TNF-α and the JNK, independently or in synergy, predict an enhanced inflammatory response and subsequent insulin resistance in Dahl S rats in excessive salt environment?

Finally, to better understand the combined role of these variations on glucose metabolism, the following question will be addressed:

Question 3: What are the functional consequences of gene variations on the rate of glucose delivery, the rate of glucose transport and the rate of glucose phosphorylation in Dahl S rats?

The general hypothesis is that "high-salt diet in combination with defects in candidate genes along the insulin signaling and inflammatory pathways predicts susceptibility to high salt-induced insulin resistance in Dahl S rats".

Available only for authorised users

DeFronzo RA, Ferrannini E: Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991, 14 (3): 173-194. 10.2337/diacare.14.3.173.PubMed

Reaven G: Role of insulin resistance in human disease. Diabetes. 1988, 37: 1595-10.2337/diabetes.37.12.1595.PubMed

Reaven G: Insulin Resistance, Hypertension, and Coronary Heart Disease. J Clin Hypertens. 2003, 5: 269-10.1111/j.1524-6175.2003.01764.x.

Sievenpiper JL, Jenkins AL, Whitham DL, Vuksan V: Insulin resistance: concepts, controversies, and the role of nutrition. Can J Diet Pract Res. 2002, Spring 63 (1): 20-32. 10.3148/63.1.2002.20.PubMed

Shehata M: Genetic and dietary salt contributors to insulinresistance in Dahl salt-sensitive (S) rats. Cardiovasc Diabetol. 2008, 7: 7-10.1186/1475-2840-7-7.PubMedCentralPubMed

Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004, 24: 816-823. 10.1161/01.ATV.0000122852.22604.78.PubMed

Hu FB, Stampfer MJ: Is type 2 diabetes mellitus a vascular condition?. Arterioscler Thromb Vasc Biol. 2003, 23: 1715-1716. 10.1161/01.ATV.0000094360.38911.71.PubMed

Roebuck KA: Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Int J Mol Med. 1999, 4 (3): 223-230.PubMed

Manning RD, Meng S, Tian N: Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand. 2003, 179 (3): 243-250. 10.1046/j.0001-6772.2003.01204.x.PubMed

10.

Matsui H, Shimosawa T, Uetake Y, Wang H, Ogura S, Kaneko T, Liu J, Ando K, Fujita T: Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension. 2006, 48 (2): 225-231. 10.1161/01.HYP.0000232617.48372.cb.PubMed

11.

Dobrian AD, Schriver SD, Lynch T, Prewitt RL: Effect of salt on hypertension and oxidative stress in a rat model of diet-induced obesity. Am J Physiol Renal Physiol. 2003, 285 (4): F619-28.PubMed

12.

Taylor NE, Glocka P, Liang M, Cowley AWJ: NADPH oxidase in the renal medulla causes oxidative stress and contributes to salt-sensitive hypertension in Dahl S Rats. Hypertension. 2006, 47: 692-10.1161/01.HYP.0000203161.02046.8d.PubMed

13.

Reddy SY, Leclerc F, Karplus M: DNA polymorphism: a comparison of force fields for nucleic acids. Biophys J. 2003, 84 (3): 1421-1449.PubMedCentralPubMed

14.

Zinchenko AA, Yoshikawa K: Na+ shows a markedly higher potential than K+ in DNA compaction in a crowded environment. Biophys J. 2005, 88: 4118-4123. 10.1529/biophysj.104.057323.PubMedCentralPubMed

15.

St Lezin E, Simonet L, Pravenec M, Kurtz TW: Hypertensive strains and normotensive 'control' strains. How closely are they related?. Hypertension. 1992, 19: 419-424.PubMed

16.

Reaven GM, Twersky J, Chang H: Abnormalities of carbohydrate and lipid metabolism in Dahl rats. Hypertension. 1991, 18: 630-635.PubMed

17.

Buchanan TA, Sipos GF, Gadalah S, Yip KP, Marsh DJ, Hsueh W, Bergman RN: Glucose tolerance and insulin action in rats with renovascular hypertension. Hypertension. 1991, 18 (3): 341-347.PubMed

18.

Tomiyama H, Kushiro T, Abeta H, Kurumatani H, Taguchi H, Kuga N, Saito F, Kobayashi F, Otsuka Y, Kanmatsuse K: Blood pressure response to hyperinsulinemia in salt-sensitive and salt-resistant rats. Hypertension. 1992, 20 (5): 596-600.PubMed

19.

Ogihara T, Asano T, Ando K, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Abe M, Fukushima Y, Kikuchi M, Fujita T: High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats. Hypertension. 2002, 40 (1): 83-89. 10.1161/01.HYP.0000022880.45113.C9.PubMed

20.

Sechi LA, Griffin CA, Zingaro L, Catena C, De Carli S, Schambelan M, Bartoli E: Glucose metabolism and insulin receptor binding and mRNA levels in tissues of Dahl hypertensive rats. Am J Hypertens. 1997, 10 (11): 1223-1230. 10.1016/S0895-7061(97)00220-3.PubMed

21.

Garvey WT, Birnbaum MJ: Cellular insulin action and insulin resistance. Baillieres Clin Endocrinol Metab. 1993, 7: 785-873. 10.1016/S0950-351X(05)80237-X.PubMed

22.

Cheatham B, Kahn CR: Insulin action and the insulin signaling network. Endocr Rev. 1995, 16: 117-142. 10.1210/er.16.2.117.PubMed

23.

Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF: Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature. 1991, 352: 73-77. 10.1038/352073a0.PubMed

24.

Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG, Glasheen E, Lane WS, Pierce JH, White MF: Role of IRS-2 in insulin and cytokine signaling. Nature. 1995, 377: 173-177. 10.1038/377173a0.PubMed

25.

Laakso M, Malkki M, Kekalainen P, Kuusisto J, Deeb SS: Insulin receptor substrate-1 variants in non-insulin-dependent diabetes. J Clin Invest. 1994, 94: 1141-1146. 10.1172/JCI117429.PubMedCentralPubMed

26.

Lavan BE, Fantin VR, Chang ET, Lane WS, Keller SR, Lienhard GE: A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J Biol Chem. 1997, 272 (34): 21403-21407. 10.1074/jbc.272.34.21403.PubMed

27.

Paz K, Voliovitch H, Hadari YR, Roberts CT, LeRoith D, Zick Y: Interaction between the insulin receptor and its downstream effectors. Use of individually expressed receptor domains for structure/function analysis. J Biol Chem. 1996, 271 (12): 6998-7003. 10.1074/jbc.271.25.15084.PubMed

28.

Almind K, Inoue G, Pedersen O, Kahn CR: A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest. 1996, 97 (11): 2569-2575. 10.1172/JCI118705.PubMedCentralPubMed

29.

Berger D, Barroso I, Soos M, Yeo G, Schafer AJ, O'Rahilly S, Whitehead JP: Genetic variants of insulin receptor substrate-1 (IRS-1) in syndromes of severe insulin resistance. Functional analysis of Ala513Pro and Gly1158Glu IRS-1. Diabet Med. 2002, 19 (10): 804-809. 10.1046/j.1464-5491.2002.00779.x.PubMed

30.

Celi FS, Negri C, Tanner K, Raben N, De Pablo F, Rovira A, Pallardo LF, Martin-Vaquero P, Stern MP, Mitchell BD, Shuldiner AR: Molecular scanning for mutations in the insulin receptor substrate-1 (IRS-1) gene in Mexican Americans with Type 2 diabetes mellitus. Diabetes Metab Res Rev. 2000, 16 (5): 370-377. 10.1002/1520-7560(2000)9999:9999<::AID-DMRR129>3.0.CO;2-B.PubMed

31.

Clausen JO, Hansen T, Bjorbaek C, Echwald SM, Urhammer SA, Rasmussen S, Andersen CB, Hansen L, Almind K, Winther K: Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet. 1995, 346 (8972): 397-402. 10.1016/S0140-6736(95)92779-4.PubMed

32.

Imai Y, Fusco A, Suzuki Y, Lesniak MA, D'Alfonso R, Sesti G, Bertoli A, Lauro R, Accili D, Taylor SI: Variant sequences of insulin receptor substrate-1 in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1994, 79 (6): 1655-1658. 10.1210/jc.79.6.1655.PubMed

33.

Le Fur S, Le Stunff C, Bougneres P: Increased insulin resistance in obese children who have both 972 IRS-1 and 1057 IRS-2 polymorphisms. Diabetes. 2002, 51 (Suppl 3): S304-7. 10.2337/diabetes.51.2007.S304.PubMed

34.

Lei HH, Coresh J, Shuldiner AR, Boerwinkle E, Brancati FL: Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: the Atherosclerosis Risk in Communities Study. Diabetes. 1999, 48 (9): 1868-1872. 10.2337/diabetes.48.9.1868.PubMed

35.

Mammarella S, Creati B, Esposito DL, Arcuri P, Della Loggia F, Capani F, Mariani-Costantini R, Caramia FG, Battista P, Cama A: Novel allele of the insulin receptor substrate-1 bearing two non-conservative amino acid substitutions in a patient with noninsulin-dependent diabetes mellitus. Mutations in brief no. 130. Online. Hum Mutat. 1998, 11 (5): 411-10.1002/(SICI)1098-1004(1998)11:5<411::AID-HUMU12>3.0.CO;2-#.PubMed

36.

't Hart LM, Nijpels G, Dekker JM, Maassen JA, Heine RJ, van Haeften TW: Variations in insulin secretion in carriers of gene variants in IRS-1 and -2. Diabetes. 2002, 51 (3): 884-887. 10.2337/diabetes.51.3.884.PubMed

37.

Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R: Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001, 15 (12): 2099-2111. 10.1096/fj.01-0009rev.PubMed

38.

Sun XJ, Crimmins DL, Myers MG, Miralpeix M, White MF: Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol Cell Biol. 1993, 13 (12): 7418-7428.PubMedCentralPubMed

39.

Qiao LY, Zhande R, Jetton TL, Zhou G, Sun XJ: In vivo phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in insulin-resistant rodents. J Biol Chem. 2002, 277: 26530-26539. 10.1074/jbc.M201494200.PubMed

40.

Draznin B: Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes. 2006, 55 (8): 2392-2397. 10.2337/db06-0391.PubMed

41.

Greene MW, Sakaue H, Wang L, Alessi DR, Roth RA: Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by Serine 312 phosphorylation. J Biol Chem. 2003, 278 (10): 8199-8211. 10.1074/jbc.M209153200.PubMed

42.

Liu YF, Herschkovitz A, Boura-Halfon S, Ronen D, Paz K, Leroith D, Zick Y: Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate 1 function and promotes insulin resistance. Mol Cell Biol. 2004, 24 (21): 9668-9681. 10.1128/MCB.24.21.9668-9681.2004.PubMedCentralPubMed

43.

Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y: A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem. 1997, 272 (47): 29911-29918. 10.1074/jbc.272.47.29911.PubMed

44.

Asano T, Ogihara T, Katagiri H, Sakoda H, Ono H, Fujishiro M, Anai M, Kurihara H, Uchijima Y: Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs. Curr Med Chem. 2004, 11 (20): 2717.PubMed

45.

Ruiz-Opazo N, Cloix JF, Melis MG, Xiang XH, Herrera VL: Characterization of a sodium-response transcriptional mechanism. Hypertension. 1997, 30 (2 Pt 1): 191-198.PubMed

46.

Kitiyakara C, Chabrashvili T, Chen Y, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS: Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol. 2003, 14 (11): 2775-2782. 10.1097/01.ASN.0000092145.90389.65.PubMed

47.

Hansen LL, Ikeda Y, Olsen GS, Busch AK, Mosthaf L: Insulin signaling is inhibited by micromolar concentrations of H(2)O(2). Evidence for a role of H(2)O(2) in tumor necrosis factor alpha-mediated insulin resistance. J Biol Chem. 1999, 274: 25078-25084. 10.1074/jbc.274.35.25078.PubMed

48.

Rudich A, Tirosh A, Potashnik R, Hemi R, Kanety H, Bashan N: Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes. 1998, 47 (10): 1562-1569. 10.2337/diabetes.47.10.1562.PubMed

49.

Tirosh A, Potashnik R, Bashan N, Rudich A: Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem. 1999, 274 (15): 10595-10602. 10.1074/jbc.274.15.10595.PubMed

50.

Talior I, Yarkoni M, Bashan N, Eldar-Finkelman H: Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. Am J Physiol Endocrinol Metab. 2003, 285 (2): E295-302.PubMed

51.

Fujita M, Ando K, Nagae A, Fujita T: Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in salt-sensitive hypertension. Hypertension. 2007, 50 (2): 360-367. 10.1161/HYPERTENSIONAHA.107.091009.PubMed

52.

Gu JW, Tian N, Shparago M, Tan W, Bailey AP, Manning RD: Renal NF-kappaB activation and TNF-alpha upregulation correlate with salt-sensitive hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2006, 291 (6): R1817-24.PubMed

53.

Hamaguchi A, Kim S, Izumi Y, Iwao H: Chronic activation of glomerular mitogen-activated protein kinases in Dahl salt-sensitive rats. J Am Soc Nephrol. 2000, 11 (1): 39-46. 10.1159/000017212.PubMed

54.

Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A: Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem. 1995, 270 (40): 23780-23784. 10.1074/jbc.270.40.23780.PubMed

55.

56.

Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A: Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993, 268 (35): 26055-26058.PubMed

57.

Aguirre V, Uchida T, Yenush L, Davis R, White MF: The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000, 275 (12): 9047-9054. 10.1074/jbc.275.12.9047.PubMed

58.

Venkatesha RT, Ahamed J, Nuesch C, Zaidi AK, Ali H: Platelet-activating factor-induced chemokine gene expression requires NF-kappaB activation and Ca2+/calcineurin signaling pathways. Inhibition by receptor phosphorylation and beta-arrestin recruitment. J Biol Chem. 2004, 279 (43): 44606-44612. 10.1074/jbc.M408035200.PubMed

59.

Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001, 108 (3): 437-446.PubMedCentralPubMed

60.

Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001, 293 (5535): 1673-1677. 10.1126/science.1061620.PubMed

61.

Wasserman DH, Ayala JE: Interaction of physiological mechanisms in control of muscle glucose uptake. Clin Exp Pharmacol Physiol. 2005, 32 (4): 319-323. 10.1111/j.1440-1681.2005.04191.x.PubMed

62.

Manchester J, Kong X, Nerbonne J, Lowry OH, Lawrence JC: Glucose transport and phosphorylation in single cardiac myocytes: rate-limiting steps in glucose metabolism. Am J Physiol. 1994, 266 (Pt 1): E326-33.PubMed

63.

Furler SM, Jenkins AB, Storlien LH, Kraegen EW: In vivo location of the rate-limiting step of hexose uptake in muscle and brain tissue of rats. Am J Physiol. 1991, 261 (3 Pt 1): E337-47.PubMed

64.

Kubo K, Foley JE: Rate-limiting steps for insulin-mediated glucose uptake into perfused rat hindlimb. Am J Physiol. 1986, 250 (1 Pt 1): E100-2.PubMed

65.

Saavedra JM, Del Carmine R, McCarty R, Guicheney P, Weise V, Iwai J: Increased adrenal catecholamines in salt-sensitive genetically hypertensive Dahl rats. Am J Physiol. 1983, 245 (5 Pt 1): H762-6.PubMed

66.

Rizza RA, Cryer PE, Haymond MW, Gerich JE: Adrenergic mechanisms of catecholamine action on glucose homeostasis in man. Metabolism. 1980, 29 (11 Suppl 1): 1155-1163. 10.1016/0026-0495(80)90025-6.PubMed

67.

Rizza RA, Cryer PE, Haymond MW, Gerich JE: Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest. 1980, 65 (3): 682-689. 10.1172/JCI109714.PubMedCentralPubMed

68.

Chiasson JL, Shikama H, Chu DT, Exton JH: Inhibitory effect of epinephrine on insulin-stimulated glucose uptake by rat skeletal muscle. J Clin Invest. 1981, 68 (3): 706-713. 10.1172/JCI110306.PubMedCentralPubMed

69.

James DE, Burleigh KM, Kraegen EW: In vivo glucose metabolism in individual tissues of the rat. Interaction between epinephrine and insulin. J Biol Chem. 1986, 261 (14): 6366-6374.PubMed

70.

Jensen J, Aslesen R, Ivy JL, Brors O: Role of glycogen concentration and epinephrine on glucose uptake in rat epitrochlearis muscle. Am J Physiol. 1997, 272 (4 Pt 1): E649-55.PubMed

71.

Jensen J, Dahl HA: Adrenaline stimulated glycogen breakdown in rat epitrochlearis muscles: fibre type specificity and relation to phosphorylase transformation. Biochem Mol Biol Int. 1995, 35 (1): 145-154.PubMed

72.

Richter EA: Influence of the sympatho-adrenal system on some metabolic and hormonal responses to exercise in the rat with special reference to the effect on glycogenolysis in skeletal muscle. Acta Physiol Scand Suppl. 1984, 528: 1-42.PubMed

73.

Hansen PA, Gulve EA, Holloszy JO: Suitability of 2-deoxyglucose for in vitro measurement of glucose transport activity in skeletal muscle. J Appl Physiol. 1994, 76 (2): 979-985.PubMed

74.

Lueck JD, Fromm HJ: Kinetics, mechanism, and regulation of rat skeletal muscle hexokinase. J Biol Chem. 1974, 249 (5): 1341-1347.PubMed

75.

Challiss RA, Lozeman FJ, Leighton B, Newsholme EA: Effects of the beta-adrenoceptor agonist isoprenaline on insulin-sensitivity in soleus muscle of the rat. Biochem J. 1986, 233 (2): 377-381.PubMedCentralPubMed

76.

Lee AD, Hansen PA, Schluter J, Gulve EA, Gao J, Holloszy JO: Effects of epinephrine on insulin-stimulated glucose uptake and GLUT-4 phosphorylation in muscle. Am J Physiol. 1997, 273 (3 Pt 1): C1082-7.PubMed

77.

Young DA, Wallberg-Henriksson H, Cranshaw J, Chen M, Holloszy JO: Effect of catecholamines on glucose uptake and glycogenolysis in rat skeletal muscle. Am J Physiol. 1985, 248 (5 Pt 1): C406-9.PubMed

78.

Wilson JE: Brain hexokinase. A proposed relation between soluble-particulate distribution and activity in vivo. J Biol Chem. 1968, 243 (13): 3640-3647.PubMed

79.

Sechi LA: Mechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity. J Hypertens. 1999, 17 (9): 1229-1237. 10.1097/00004872-199917090-00001.PubMed

80.

Sechi LA, Bartoli E: Mechanisms of insulin resistance leading to hypertension: what we can learn from experimental models. J Investig Med. 1997, 45 (5): 238-251.PubMed

81.

Shehata MF, Leenen FH, Tesson F: Sequence analysis of coding and 3' and 5' flanking regions of the epithelial sodium channel alpha, beta, and gamma genes in Dahl S versus R rats. BMC Genet. 2007, 8: 35-10.1186/1471-2156-8-35.PubMedCentralPubMed

82.

Shehata MF, Leenen FHH, Tesson F: Polymorphisms in 5'UTR of ENaC α, β and γ genes in Dahl and Wistar rats. FASEB. 2006, 20: A310-A311.

83.

Shehata MF, Tesson F, Leenen FH: Are Genetic Variations in the Coding Sequence of ENaC Alpha, Beta and/or Gamma Subunits Associated with Salt Sensitive Hypertension in Dahl Rats?. Can J Cardiology. 2005, 21: 135C.

84.

85.

Ellis LA, Taylor CF, Taylor GR: A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. Hum Mutat. 2000, 15 (6): 556-564. 10.1002/1098-1004(200006)15:6<556::AID-HUMU7>3.0.CO;2-C.PubMed

86.

Eshleman SH, Crutcher G, Petrauskene O, Kunstman K, Cunningham SP, Trevino C, Davis C, Kennedy J, Fairman J, Foley B, Kop J: Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer. J Clin Microbiol. 2005, 43 (2): 813-817. 10.1128/JCM.43.2.813-817.2005.PubMedCentralPubMed

87.

Shehata M, Shehata M, Shehata F, Pater A: Apoptosis effects of Xrel3 c-Rel/Nuclear Factor-kappa B homolog in human cervical cancer cells. Cell Biol Int. 2005, 29 (6): 429-440. 10.1016/j.cellbi.2004.12.014.PubMed

88.

Shehata M, Shehata M, Shehata F, Pater A: Dual apoptotic effect of Xrel3 c-Rel/NF-kappaB homolog in human cervical cancer cells. Cell Biol Int. 2004, 28 (12): 895-904. 10.1016/j.cellbi.2004.09.002.PubMed

89.

Shehata MF: Rel/Nuclear factor-kappa B apoptosis pathways in human cervical cancer cells. Cancer Cell Int. 2005, 5 (1): 10-10.1186/1475-2867-5-10.PubMedCentralPubMed

90.

Shehata MF, Tesson F, Leenen FH: Polymorphisms in 5'UTR of ENaC alpha, beta and gamma genes in Dahl and Wstar rats. Third Annual Research Forum for Young Investigators in Circulatory and Respiratory Health. 2006

91.

Rojas FA, Hirata AE, Saad MJ: Regulation of IRS-2 tyrosine phosphorylation in fasting and diabetes. Mol Cell Endocrinol. 2001, 183 (1-2): 63-69. 10.1016/S0303-7207(01)00597-4.PubMed

92.

Valverde AM, Benito M, Lorenzo M: The brown adipose cell: a model for understanding the molecular mechanisms of insulin resistance. Acta Physiol Scand. 2005, 183 (1): 59-73. 10.1111/j.1365-201X.2004.01384.x.PubMed

93.

Valverde AM, Benito M: The brown adipose cell: a unique model for understanding the molecular mechanism of insulin resistance. Mini Rev Med Chem. 2005, 5 (3): 269-278.PubMed

94.

Cengel KA, Freund GG: JAK1-dependent phosphorylation of insulin receptor substrate-1 (IRS-1) is inhibited by IRS-1 serine phosphorylation. J Biol Chem. 1999, 274 (39): 27969-27974. 10.1074/jbc.274.39.27969.PubMed

95.

Sechi LA, Griffin CA, Zingaro L, Valentin JP, Bartoli E, Schambelan M: Effects of angiotensin II on insulin receptor binding and mRNA levels in normal and diabetic rats. Diabetologia. 1997, 40 (7): 770-777. 10.1007/s001250050748.PubMed

96.

Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science. 1996, 273: 1516-1517. 10.1126/science.273.5281.1516.PubMed

97.

Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001, 68 (4): 978-989. 10.1086/319501.PubMedCentralPubMed

98.

Holmang A, Mimura K, Bjorntorp P, Lonnroth P: Interstitial muscle insulin and glucose levels in normal and insulin-resistant Zucker rats. Diabetes. 1997, 46 (11): 1799-1804. 10.2337/diabetes.46.11.1799.PubMed

99.

Holmang A, Muller M, Andersson OK, Lonnroth P: Minimal influence of blood flow on interstitial glucose and lactate-normal and insulin-resistant muscle. Am J Physiol. 1998, 274 (3 Pt 1): E446-52.PubMed

100.

Muller M, Holmang A, Andersson OK, Eichler HG, Lonnroth P: Measurement of interstitial muscle glucose and lactate concentrations during an oral glucose tolerance test. Am J Physiol. 1996, 271 (6 Pt 1): E1003-7.PubMed

101.

Halseth AE, Bracy DP, Wasserman DH: Functional limitations to glucose uptake in muscles comprised of different fiber types. Am J Physiol Endocrinol Metab. 2001, 280 (6): E994-9.PubMed

102.

Halseth AE, Bracy DP, Wasserman DH: Limitations to basal and insulin-stimulated skeletal muscle glucose uptake in the high-fat-fed rat. Am J Physiol Endocrinol Metab. 2000, 279 (5): E1064-71.PubMed

103.

Halseth AE, Bracy DP, Wasserman DH: Limitations to exercise- and maximal insulin-stimulated muscle glucose uptake. J Appl Physiol. 1998, 85 (6): 2305-2313.PubMed

104.

Petersen HA, Fueger PT, Bracy DP, Wasserman DH, Halseth AE: Fiber type-specific determinants of Vmax for insulin-stimulated muscle glucose uptake in vivo. Am J Physiol Endocrinol Metab. 2003, 284 (3): E541-8.PubMed

105.

O'Doherty RM, Halseth AE, Granner DK, Bracy DP, Wasserman DH: Analysis of insulin-stimulated skeletal muscle glucose uptake in conscious rat using isotopic glucose analogs. Am J Physiol. 1998, 274 (2 Pt 1): E287-96.PubMed

106.

Fiorani M, De Sanctis R, Saltarelli R, Stocchi V: Hexokinase inactivation induced by ascorbic acid/Fe(II) in rabbit erythrocytes is independent of glutathione-reductive processes and appears to be mediated by dehydroascorbic acid. Arch Biochem Biophys. 1997, 342 (2): 191-196. 10.1006/abbi.1997.9963.PubMed

107.

Fiorani M, De Sanctis R, Scarlatti F, Vallorani L, De Bellis R, Serafini G, Bianchi M, Stocchi V: Dehydroascorbic acid irreversibly inhibits hexokinase activity. Mol Cell Biochem. 2000, 209 (1-2): 145-153. 10.1023/A:1007168032289.PubMed

108.

Wilden PA, Siddle K, Haring E, Backer JM, White MF, Kahn CR: The role of insulin receptor kinase domain autophosphorylation in receptor-mediated activities. Analysis with insulin and anti-receptor antibodies. J Biol Chem. 1992, 267 (19): 13719-13727.PubMed

109.

Kanai F, Ito K, Todaka M, Hayashi H, Kamohara S, Ishii K, Okada T, Hazeki O, Ui M, Ebina Y: Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinase. Biochem Biophys Res Commun. 1993, 195 (2): 762-768. 10.1006/bbrc.1993.2111.PubMed

110.

Moran A, Steffen LM, Jacobs DR, Steinberger J, Pankow JS, Hong CP, Tracy RP, Sinaiko AR: Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care. 2005, 28 (7): 1763-1768. 10.2337/diacare.28.7.1763.PubMed

111.

Curran JE, Jowett JB, Elliott KS, Gao Y, Gluschenko K, Wang J, Abel Azim DM, Cai G, Mahaney MC, Comuzzie AG, Dyer TD, Walder KR, Zimmet P, MacCluer JW, Collier GR, Kissebah AH, Blangero J: Genetic variation in selenoprotein S influences inflammatory response. Nat Genet. 2005, 37 (11): 1234-1241. 10.1038/ng1655.PubMed

112.

Onengut-Gumuscu S, Buckner JH, Concannon P: A haplotype-based analysis of the PTPN22 locus in type 1 diabetes. Diabetes. 2006, 55 (10): 2883-2889. 10.2337/db06-0225.PubMed

113.

Onengut-Gumuscu S, Ewens KG, Spielman RS, Concannon P: A functional polymorphism (1858C/T) in the PTPN22 gene is linked and associated with type I diabetes in multiplex families. Genes Immun. 2004, 5 (8): 678-680. 10.1038/sj.gene.6364138.PubMed

114.

Zheng W, She JX: Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes. Diabetes. 2005, 54 (3): 906-908. 10.2337/diabetes.54.3.906.PubMed

115.

Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H: Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia. 2002, 45: 805-812. 10.1007/s00125-002-0829-2.PubMed

116.

Busquets S, Figueras M, Almendro V, Lopez-Soriano FJ, Argiles JM: Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine. Biochim Biophys Acta. 2006, 1760 (11): 1613-1617.PubMed

117.

Zhang YF, Yang YS, Hong J, Gu WQ, Shen CF, Xu M, Du PF, Li XY, Ning G: Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. Endocrine. 2006, 29 (3): 419-423. 10.1385/ENDO:29:3:419.PubMed

118.

Fischer CP, Perstrup LB, Berntsen A, Eskildsen P, Pedersen BK: Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol. 2005, 117 (2): 152-160. 10.1016/j.clim.2005.07.008.PubMed

119.

Anhe GF, Torrao AS, Nogueira TC, Caperuto LC, Amaral ME, Medina MC, Azevedo-Martins AK, Carpinelli AR, Carvalho CR, Curi R, Boschero AC, Bordin S: ERK3 associates with MAP2 and is involved in glucose-induced insulin secretion. Mol Cell Endocrinol. 2006, 251 (1-2): 33-41. 10.1016/j.mce.2006.02.012.PubMed

120.

Bouzakri K, Zierath JR: MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem. 2007, 282 (11): 7783-7789. 10.1074/jbc.M608602200.PubMed

121.

Tang X, Guilherme A, Chakladar A, Powelka AM, Konda S, Virbasius JV, Nicoloro SM, Straubhaar J, Czech MP: An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARgamma, adipogenesis, and insulin-responsive hexose transport. Proc Natl Acad Sci USA. 2006, 103: 2087-2092. 10.1073/pnas.0507660103.PubMedCentralPubMed

122.

Matter CM, Handschin C: RANTES (regulated on activation, normal T cell expressed and secreted), inflammation, obesity, and the metabolic syndrome. Circulation. 2007, 115 (2): 946-948. 10.1161/CIRCULATIONAHA.106.685230.PubMed

123.

Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW: CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006, 116 (1): 115-124. 10.1172/JCI24335.PubMedCentralPubMed

124.

de Silva E, Stumpf MP: HIV and the CCR5-Delta32 resistance allele. FEMS Microbiol Lett. 2004, 241: 1-12. 10.1016/j.femsle.2004.09.040.PubMed

125.

Carnesecchi S, Carpentier JL, Foti M, Szanto I: Insulin-induced vascular endothelial growth factor expression is mediated by the NADPH oxidase NOX3. Exp Cell Res. 2006, 312 (17): 3413-3424. 10.1016/j.yexcr.2006.07.003.PubMed

126.

Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, Lambeth JD, Goldstein BJ: The NAD(P)H oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal transduction. Mol Cell Biol. 2004, 24: 1844-1854. 10.1128/MCB.24.5.1844-1854.2004.PubMedCentralPubMed

127.

Konheim YL, Wolford JK: Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum Genet. 2003, 113: 377-381. 10.1007/s00439-003-1000-y.PubMed

128.

Kaaman M, Ryden M, Axelsson T, Nordstrom E, Sicard A, Bouloumie A, Langin D, Arner P, Dahlman I: ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance. Int J Obes (Lond). 2006, 30: 447-452. 10.1038/sj.ijo.0803147.

129.

Ohtoshi K, Yamasaki Y, Gorogawa S, Hayaishi-Okano R, Node K, Matsuhisa M, Kajimoto Y, Hori M: Association of (-)786T-C mutation of endothelial nitric oxide synthase gene with insulin resistance. Diabetologia. 2002, 45 (11): 1594-1601. 10.1007/s00125-002-0922-6.PubMed

130.

Perreault M, Marette A: Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med. 2001, 7 (10): 1138-1143. 10.1038/nm1001-1138.PubMed

131.

Tsuchiyama N, Takamura T, Ando H, Sakurai M, Shimizu A, Kato K, Kurita S, Kaneko S: Possible role of alpha-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes. Diabetes Care. 2007, 30 (10): 2583-2587. 10.2337/dc07-0066.PubMed

132.

Labonte ED, Kirby RJ, Schildmeyer NM, Cannon AM, Huggins KW, Hui DY: Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia. Diabetes. 2006, 55 (4): 935-941. 10.2337/diabetes.55.04.06.db05-1286.PubMedCentralPubMed

133.

Ensemble. [http://www.ensembl.org]

Title: Important genetic checkpoints for insulin resistance in salt-sensitive (S) Dahl rats
Author: Marlene F Shehata
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2008
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/1475-2840-7-19

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Prevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjects

Diacylglycerol kinase ζ inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment

Exercise training enhanced myocardial endothelial nitric oxide synthase (eNOS) function in diabetic Goto-Kakizaki (GK) rats

Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage